Yet the stock failed to move higher. However, the lack of a response comes as no surprise given this company's tiny size and the overall economic backdrop. The big fund mangers whose attention we so desperately need, were sidelined with catastrophic swings in big name stocks that created major hits in their holdings. The IBB was especially hard hit as were the smaller biotechs like CANF so the fact that the decline was halted speaks well for the future. But many are still sitting on sidelines with their cash waiting to jump back in. When they see us, hopefully they will remember the very promising IP we have and the clinical trial results that could put significant ownership in this company out of their reach in the very near future..
MNKD tried as well. A revolutionary new inhale-able insulin on the market goes unnoticed because the insurers won't cover the cost and getting a prescription mandates a 2 step process for those that do. Today, Sanofi announced that they would no longer be carrying Afrezza in their product lineup and MNKD has CRATERED to quote the MOTLEY FOOL. It is currently trading at .84c and likely on its way to .sub .50c by the end of the day.
Its amazing how "the system" just chews up and spits out perfectly good ideas; life saving technology, all so that a bunch of self serving government bureaucrats can protect their conflicts of interest. Amazing....and sad.